Graves’ disease occurs when the thyroid gland becomes overactive and produces more thyroid hormones. This may lead to other medical complications, including issues with your heart, bones ...

The active phase can last anywhere from 6 months to 2 years. Thyroid eye disease is most common in people with Graves' ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Key Features of Graves' Disease: - Goiter: An enlarged thyroid gland may appear as a noticeable swelling in the neck. - Eye Symptoms: A condition called Graves' ophthalmopathy affects some ...

Topline results have been announced from a Phase 2/3 trial assessing linsitinib for the treatment of active, moderate to ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...

Viridian Shares Soar After Latest Trial Success for Thyroid Eye Disease Drug Viridian Therapeutics ... over radioactive iodine in initial Graves’ disease treatment, and new investigational ...

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release ...

COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.

Graves' Disease [GD] is characterized as an autoimmune ... in the phase 3 study for the treatment of patients with Thyroid Eye Disease [TED]. The risk here is that there is no assurance that ...

Kamuvudine-9 is under clinical development by Inflammasome Therapeutics and currently in Phase I for Graves' Ophthalmopathy.

The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.